MedDataX Logo

The Epidemic Status and Development Trend of Hepatitis C Virus Infection in Pregnant Women in Xi'an

NCT ID: NCT06952036

Last Updated: 2025-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

200000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-04-25

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of this study are to improve HCV linkage-to-care in Chinese women and provide theoretical basis for the scientific formulation of HCV prevention and control strategies for pregnant women.

To understand the epidemiological changes and status of hepatitis C virus (HCV) infection in pregnant women in Shaanxi province in recent 10 years, and to analyze the main influencing factors of hepatitis C infection in pregnant women.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HCV Infection HCV Elimination

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Hepatitis C HCV elimination Women of childbearing age

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregnant women who had an antenatal visit or gave birth between 2014 and 2023.

Standard Direct-acting antivirals (DAA) treatment procedures for patients with hepatitis C

Intervention Type PROCEDURE

Initiated Standard DAA treatment among HCV RNA positive patients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard Direct-acting antivirals (DAA) treatment procedures for patients with hepatitis C

Initiated Standard DAA treatment among HCV RNA positive patients.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Pregnant women or parturient women confirmed by blood HCG test.
2. Patients aged 18 years old and above.
3. Patients with HCV antibody seropositive or HCV RNA positive from 2014-2023.

Exclusion Criteria

1. Patients without valid telephone numbers.
2. Duplicate records: For duplicate records of the same pregnant woman, only one record should be kept.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

First Affiliated Hospital Xi'an Jiaotong University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

He Yingli

Director of Department of Infectious Diseases, the First Affiliated Hospital of Jiaotong University

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yingli He

Role: CONTACT

Phone: +86-18991232863

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

XJTU1AF2024LSYY-413

Identifier Type: -

Identifier Source: org_study_id